Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Cash from Investing Activities (2016 - 2025)

Ironwood Pharmaceuticals' Cash from Investing Activities history spans 16 years, with the latest figure at $1000.0 for Q4 2025.

  • For Q4 2025, Cash from Investing Activities changed N/A year-over-year to $1000.0; the TTM value through Dec 2025 reached -$34000.0, up 76.06%, while the annual FY2025 figure was -$34000.0, 76.06% up from the prior year.
  • Cash from Investing Activities for Q4 2025 was $1000.0 at Ironwood Pharmaceuticals, up from -$2000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $27000.0 in Q4 2022 and bottomed at -$999.5 million in Q2 2023.
  • The 5-year median for Cash from Investing Activities is -$44500.0 (2024), against an average of -$64.2 million.
  • The largest annual shift saw Cash from Investing Activities surged 121.09% in 2022 before it crashed 1135686.36% in 2023.
  • A 5-year view of Cash from Investing Activities shows it stood at -$128000.0 in 2021, then soared by 121.09% to $27000.0 in 2022, then tumbled by 15611.11% to -$4.2 million in 2023, then skyrocketed by 99.62% to -$16000.0 in 2024, then skyrocketed by 106.25% to $1000.0 in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Cash from Investing Activities are $1000.0 (Q4 2025), -$2000.0 (Q3 2025), and -$2000.0 (Q2 2025).